Multiple sclerosis is characterized by repetitive symptomatic episodes or progressive degeneration of the nervous system with visual symptoms (blurry or double vision), blindness in one eye, muscle weakness, numbness and tingling in focal areas of the body, incoordination, difficulty walking, imbalance, urinary frequency and incontinence, pain, tremor, dizziness, hearing loss cognitive symptoms, emotional changes, and depression.

HBOT works in MS by repairing the wounds to the nerve fibers and inhibiting inflammation. Benefits from HBOT with Dr. Harch include increased mobility, reduced fatigue, and improved equilibratory coordination. Urinary symptoms also improve, as well as nystagmus and spasticity. The most rigorous study ever performed using HBOT-treatment of MS was published in one of the most prestigious medical journals, the New England Journal of Medicine, in 1983. The study showed a statistically significant improvement in HBOT-treated MS patients compared to the control group. Patients experienced increased mobility, reduced fatigability, and improved equilibratory coordination, along with improved urinary symptoms, improvements in nystagmus (rapid beating of the eyes), and improvements in spasticity. At the one year follow-up, deterioration occurred in 12% of the HBOT group vs. 55% of the control group. In other words, HBOT had a sustained effect and prevented further deterioration.   When ten to fourteen year follow-up studies were performed on MS patients in England receiving long-term treatment (one treatment every 2-4 weeks) patients demonstrate maintenance and even improvement in neurological function.